Filing summary
Company: Iovance Biotherapeutics, Inc. Filing: Form 8-K, dated September 29, 2026.
Business context and reporting period
The filing reports that Iovance issued a press release on September 29, 2026, updating its full-year 2026 revenue guidance. The press release is identified as Exhibit 99.1, but its text is not included in the supplied filing content.
Financial performance and changes
The filing provides no revenue figures, profit, cash flow, margins, debt, liquidity metrics, or other financial results. It does not state the prior guidance or quantify the change, so the revised outlook and comparison cannot be determined from the supplied text.
Outlook, risks, and unusual items
The only outlook information provided is that full-year 2026 revenue guidance was updated. The filing text does not provide a clear value or explain the reason for the update. No specific risks, contingencies, or unusual items are described.
Facts for investors to verify
- Review Exhibit 99.1 for the revised full-year 2026 revenue guidance and prior guidance.
- Check the press release for management’s explanation of the update and any associated assumptions or risks.